Style | Citing Format |
---|---|
MLA | Nematollahi P, et al.. "Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia." Pediatric Hematology and Oncology, vol. 41, no. 1, 2024, pp. 54-64. |
APA | Nematollahi P, Arabi S, Mansourian M, Yousefian S, Moafi A, Mostafavi SN, Alavi Naeini A, Ebrahimi A, Ebrahimpour K, Amin MM, Kavosh A, Mahmoudi Kohi S, Kelishadi R (2024). Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 41(1), 54-64. |
Chicago | Nematollahi P, Arabi S, Mansourian M, Yousefian S, Moafi A, Mostafavi SN, Alavi Naeini A, et al.. "Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia." Pediatric Hematology and Oncology 41, no. 1 (2024): 54-64. |
Harvard | Nematollahi P et al. (2024) 'Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia', Pediatric Hematology and Oncology, 41(1), pp. 54-64. |
Vancouver | Nematollahi P, Arabi S, Mansourian M, Yousefian S, Moafi A, Mostafavi SN, et al.. Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology. 2024;41(1):54-64. |
BibTex | @article{ author = {Nematollahi P and Arabi S and Mansourian M and Yousefian S and Moafi A and Mostafavi SN and Alavi Naeini A and Ebrahimi A and Ebrahimpour K and Amin MM and Kavosh A and Mahmoudi Kohi S and Kelishadi R}, title = {Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia}, journal = {Pediatric Hematology and Oncology}, volume = {41}, number = {1}, pages = {54-64}, year = {2024} } |
RIS | TY - JOUR AU - Nematollahi P AU - Arabi S AU - Mansourian M AU - Yousefian S AU - Moafi A AU - Mostafavi SN AU - Alavi Naeini A AU - Ebrahimi A AU - Ebrahimpour K AU - Amin MM AU - Kavosh A AU - Mahmoudi Kohi S AU - Kelishadi R TI - Potential Role of Serum Vitamin D As a Risk Factor in Pediatric Acute Lymphoblastic Leukemia JO - Pediatric Hematology and Oncology VL - 41 IS - 1 SP - 54 EP - 64 PY - 2024 ER - |